SMARCA4 and adenocarcinoma: The investigation by Miralli et al. is one of the smaller studies that addressed whether co-occurring mutations in KEAP1, STK11, PBRM1 (Polybromo 1), and SMARCA4 (Mitotic Growth And Transcription Activator) genes could facilitate the identification of adenocarcinoma patients unresponsive to ICIs.